Krka DDLTS:0HLK 84 Interest Coverage is 756.99 as of Mar. 2026, which is 18% above its 10-year median of 642.74. GuruFocus rates LTS:0HLK with a GF Score™ of 84/100 and a GF Value™ of €37.63 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 684 Drug Manufacturers companies, Krka DD ranks better than 75.29% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Krka DD's
Operating Income
for the
three
months ended in Mar. 2026 was €154 Mil. Krka DD's Interest Expense for the
three
months ended in Mar. 2026 was €-0 Mil.
Krka DD's interest coverage for the quarter that ended in Mar. 2026 was 756.99.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Krka DD has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Krka DD's Interest Coverage or its related term are showing as below:
LTS:0HLK'
s Interest Coverage Range Over the Past 10 Years
Min: 66.45 Med: 642.74 Max: 1211.85
Current: 69.95
LTS:0HLK's Interest Coverage is ranked better than 75.29% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs LTS:0HLK: 69.95
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Krka DD Interest Coverage Related Terms
Krka DD Interest Coverage Historical Data
* Premium members only.
The historical data trend for Krka DD's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0HLK vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Krka DD's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (LTS:0HLK) has a Interest Coverage of 756.99 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Krka DD and its competitors. This is 18% above median its historical median of 642.74. Over the past decade, Krka DD's Interest Coverage has ranged from 66.45 to 1,211.85. According to the industry distribution chart, Krka DD ranks #169 out of 684 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is Krka DD's Interest Coverage too high?
Krka DD's current Interest Coverage of 756.99 is 18% above median its 10-year median of 642.74. Over the past 10 years, this metric has ranged from a low of 66.45 to a high of 1,211.85. The Drug Manufacturers industry median Interest Coverage is 12.77. Krka DD's value of 756.99 is 5830.2% above this industry median. Based on the distribution chart, Krka DD ranks #169 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #169 out of 684 companies for Interest Coverage. This places Krka DD in the top 25% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.77. Krka DD's value of 756.99 is 5830.2% above this benchmark. Historically, Krka DD's own Interest Coverage has ranged from 66.45 to 1,211.85 over the past decade. While the company's 10-year median is 642.74 vs. the industry median of 12.77, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Interest Coverage of 756.99 is 5830.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Interest Coverage is 756.99, which is 18% above median its own 10-year median of 642.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €37.63, compared to a current price of €64.80 — trading 72.2% above its estimated fair value. The current Interest Coverage is 756.99, which is 18% above median its 10-year median of 642.74 and 5830.2% above the Drug Manufacturers industry median of 12.77. Krka DD's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current Interest Coverage is 756.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 72.2% above its estimated GF Value™ of €37.63.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for LTS:0HLK:
Interest Coverage: 756.99 (18% above median its 10-year median of 642.74)
GF Value™: €37.63 vs. price of €64.80 (72.2% above fair value)
Industry Position: 5830.2% above the Drug Manufacturers median (#169 of 684)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
84GF Score
Get the complete analysis for LTS:0HLK
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
